Biotechnology
Agios Pharmaceuticals discontinues tebapivat in sickle cell disease after Phase 2 data fails to show meaningful differentiation from competitors, removing the company's backup narrative and concentrating risk on mitapivat's November FDA decision.
Policy
The FDA's finalized guidance on psychedelic drug development provides the clearest regulatory roadmap yet for companies developing psilocybin, MDMA, and related compounds as treatments for psychiatric disorders.
Biotechnology
Samsung Biologics' $1.81 billion bid for Swiss peptide manufacturer PolyPeptide Group is not just an M&A story. It is a strategic play for control of the GLP-1 drug supply chain, and a signal of where the CDMO industry is heading.
Biotechnology
Merck's $31.7 billion oncology drug has transformed oncology, but combining immunotherapy with radiation remains a major challenge. Tomorrow, Alpha Tau will present the first prospective data testing whether its targeted alpha radiation can change that equation.
Biotechnology
How a drug rescued from Pfizer's shelf became Revtorpyk, the first medicine to simultaneously block all major components of the PI3K/AKT/mTOR pathway in breast cancer—and what it means for oncology's future.
Biotechnology
Biogen's tau-targeting drug BIIB080 demonstrates a 26% slowing of cognitive decline, matching approved Alzheimer's therapies and potentially validating an entirely new treatment category for the disease.
Biotechnology
A first-in-human study from Northwell Health's Feinstein Institutes shows that a wearable ear device can activate the vagus nerve to accelerate blood clotting, opening a new frontier in bioelectronic medicine for hemorrhage control.
Biotechnology
GSK and Hansoh's ris-rez became the first B7-H3-targeted ADC to demonstrate an overall survival benefit in a Phase 3 trial. Here is what the ARTEMIS-008 result means for small-cell lung cancer patients, the ADC field, and GSK's oncology ambitions.
Pharmaceuticals
AstraZeneca and Ionis's eplontersen failed the CARDIO-TTRansform Phase 3 trial in ATTR-CM. The result reveals a deeper challenge: what happens when the standard of care evolves faster than the trial designed to test against it.
Biotechnology
The FDA approved Trutakna (atacicept) for IgA nephropathy on July 7, 2026, making it the first BAFF/APRIL dual inhibitor cleared for the disease. Here is what the approval means for patients, the competitive landscape, and the science of kidney disease.
Biotechnology
The FDA's expansion of Casgevy to children as young as 2 years old marks a milestone for CRISPR gene therapy, but significant access barriers remain a critical challenge for families.
Biotechnology
For five years, the KRAS G12C inhibitor market in lung cancer has been a story of scientific triumph and commercial disappointment. Amgen's Lumakras and Bristol Myers Squibb's Krazati were genuine breakthroughs when they launched in 2021 and 2022, respectively. They proved that KRAS, long considered undruggable,